The Somatostatin Analog Class: SSTR1-5 Selectivity and Cyclic Structure
Somatostatin analogs are small cyclic peptides built from a single conserved β-turn, yet they read the five somatostatin receptors very differently. This explainer walks through the cyclic architecture, the SSTR1-5 subtypes, and the handful of residues that decide which receptor an analog prefers.
by Research Assistant·
Somatostatin is one of biology's more elegant puzzles: a tiny cyclic peptide that carries a single message to five different receptors, each with its own job. The compounds known collectively as the somatostatin analog class — the research materials discussed here are for research use only — are what you get when chemists take that natural message apart and rebuild it to be sturdier and more selective. Understanding the class comes down to one question: how does a small change in a peptide ring decide which of five receptors it talks to?
Think of the analog class as a structure-to-selectivity problem. We'll look at what the class actually is, how its cyclic architecture works, the five receptor subtypes it aims at, and the molecular details that make one analog prefer one receptor over another. If you're researching these compounds, that structural lens is the clearest way to make sense of why octreotide, lanreotide, and pasireotide behave so differently in receptor-binding studies.
What the Somatostatin-Analog Class Is
In plain terms, the somatostatin analog class is a small family of engineered, shorter cousins of the natural hormone somatostatin. The parent molecule, somatostatin-14 (SST-14), is itself a cyclic peptide — but a famously fragile one. In circulation it stays intact for only about one to three minutes before enzymes break it down. That instability is the whole reason the analog class exists. Researchers needed versions that hold their shape long enough to be useful in the lab.
Three compounds anchor the class. Octreotide and lanreotide are cyclic octapeptides — eight-residue rings — and formed the first generation. Pasireotide came later as a stable cyclohexapeptide with a distinctly broader receptor profile, and it's usually described as the second-generation member. Each one keeps the functional heart of somatostatin while trimming and reinforcing everything around it.
One clarification matters for anyone new to this area. Octreotide, lanreotide, and pasireotide are also the INN/USAN names of FDA-approved pharmaceutical products. Research-grade material carrying the same chemical name is not equivalent to the approved medicine and is supplied strictly for in-vitro laboratory investigation. The chemistry is shared; the regulatory status is not.
The Cyclic Architecture and the β-Turn Pharmacophore
Here's the short version: the analog class works because of a ring and a turn.
The ring that makes it stable
Closing a peptide into a cyclic peptide ring does two things at once. It locks the backbone into a more rigid, predictable shape, and it removes the loose ends that enzymes normally grab to chew a peptide apart. For a molecule that has to survive long enough to reach a receptor, that rigidity isn't a cosmetic detail — it's the difference between a compound that lasts minutes and one that lasts far longer under study conditions.
The Phe-Trp-Lys-Thr β-turn
Inside native somatostatin, four residues do almost all the work. Phenylalanine-7, tryptophan-8, lysine-9, and threonine-10 fold into a flexible β-turn motif that determines the peptide's binding affinity and biological activity. This Phe-Trp-Lys-Thr turn is the pharmacophore — the part the receptor actually reads. Every analog in the class carries this motif in some modified form.
Two residues in that turn shoulder most of the load. The lysine reaches deep into the receptor pocket and anchors itself through a salt bridge and a hydrogen bond; the tryptophan slots against a wall of aromatic phenylalanines and holds on through π-π interactions between their ring systems. Studies of lanreotide and pasireotide at their receptors make the point vividly: mutate the residues those two anchors grab, and the signaling almost completely disappears. The turn isn't just important. It's close to the whole story of engagement.
Meet the Five Receptors: SSTR1-5
The short answer: there are five somatostatin receptors, they share the same basic shape, and they hold different day jobs in the body. All five — SSTR1 through SSTR5 — belong to the G-protein-coupled receptor family, each threading back and forth across the cell membrane seven times, with the outer loops forming the ligand-binding site and the inner face coupling to signaling proteins.
Where they sit differs by tissue. SSTR2 and SSTR5 dominate in the pituitary, while SSTR2, SSTR3, and SSTR5 turn up variably in gastrointestinal tissue. That geography matters, because a compound biased toward one subtype will engage a different set of tissues than a compound biased toward another.
Downstream, the subtypes speak a common language. The primary route is inhibition of adenylyl cyclase, which lowers intracellular cyclic AMP; layered on top are phospholipase C, MAP-kinase, and PI3K/Akt pathways, plus antiproliferative signaling through the phosphatases SHP-1 and SHP-2 that, in cell-culture models, slows cell proliferation. Because all five receptors can carry versions of this signal, the interesting research question is rarely "does the analog work" but "which receptor did it choose" — and that's entirely a matter of selectivity.
How Structure Encodes Subtype Selectivity
The lead question here: if the five receptors are so similar, what makes an analog pick one? The answer lives in a small number of amino-acid swaps.
Pasireotide reaches SSTR5 through a different structural trick. Its bulky benzyl-protected tyrosine is too large to sit quietly in the pocket, so it pushes one of SSTR5's transmembrane helices outward by about 5.4 ångströms, opening a contact with a glutamine that the smaller octreotide simply can't reach. That extra handhold is a big part of why pasireotide's selectivity tilts toward SSTR5 while octreotide's stays anchored on SSTR2.
Reading the Selectivity Numbers
Selectivity in this field isn't a vibe — it's measured, usually with receptor-binding assays that report how tightly a compound holds each subtype. Seen through that lens, the class sorts into a clear pattern.
SSTR1 stays the class's hardest target. Even pasireotide binds it about tenfold more weakly than native somatostatin, and lanreotide's affinity runs nearly 200 times lower than the parent hormone. Structural comparison traces much of that gap to a single position: where SSTR2 has a glutamine that makes a friendly polar contact, SSTR1 carries a methionine that can't. Swap the methionine back to glutamine, and potency for both analogs climbs at least tenfold — a clean demonstration that subtype selectivity really can hinge on one residue.
Frequently Asked Questions
What is the somatostatin analog class?
It is a family of small, synthetic cyclic peptides modeled on the natural hormone somatostatin. The class includes octreotide, lanreotide, and pasireotide. Each keeps the core β-turn that somatostatin uses to engage its receptors, but is re-engineered to resist rapid breakdown, so the compound remains structurally intact far longer than native somatostatin in research settings.
What are the five somatostatin receptors (SSTR1-5)?
SSTR1 through SSTR5 are five related G-protein-coupled receptors that the somatostatin peptide family binds. They share the seven-transmembrane architecture of the GPCR family but differ in tissue distribution and in a handful of binding-pocket residues. Those residue differences are why one analog can strongly prefer SSTR2 while another spreads its affinity across SSTR1, 3, and 5.
Why does octreotide prefer SSTR2 while pasireotide favors SSTR5?
Structural studies show the preference comes down to a few specific residues in each receptor's binding pocket and the size of the analog's side chains. Octreotide's smaller β-turn fits SSTR2's pocket and its longer extracellular loop, while pasireotide's bulky benzyl-tyrosine pushes a transmembrane helix outward in SSTR5 to make a contact octreotide cannot, shifting its selectivity toward SSTR5.
Are somatostatin analogs the same as research peptides sold for laboratory use?
No. Octreotide, lanreotide, and pasireotide are the INN/USAN names of FDA-approved pharmaceutical products. Research-grade material carrying the same chemical name is not equivalent to, and should not be confused with, the approved drug. Research peptides are supplied strictly for in-vitro laboratory investigation, not for any human or animal use.
Putting It All Together
The most useful way to hold the somatostatin analog class in mind is as one idea presented three ways: a single conserved β-turn, mounted on slightly different cyclic scaffolds, read differently by five closely related receptors. The ring provides durability, the turn provides recognition, and a small set of pocket residues decides which subtype answers the call. That's why octreotide and lanreotide read as SSTR2 specialists while pasireotide behaves like a generalist that leans on SSTR5.
The frontier now is turning that residue-level understanding into genuinely subtype-selective designs — compounds that engage exactly one receptor and leave the others alone. For researchers, the takeaway is that structure is destiny here: read the turn and the pocket, and you can predict the selectivity. To go deeper on the building blocks, the linked explainers on cyclic peptides, β-turns, D-amino acids, and binding assays are good next stops.
For research use only. Not for human or animal
consumption of any kind. The information in this article is for
educational purposes only and is not intended to diagnose, treat,
cure, or prevent any disease. The statements made have not been
evaluated by the U.S. Food and Drug Administration. These products
are NOT FDA APPROVED. Please consult with a licensed healthcare
professional before making any decisions regarding your health
or research.
Optides LLC is a chemical supplier. Optides LLC is not a
compounding pharmacy or chemical compounding facility as defined
under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC
is not an outsourcing facility as defined under 503B of the Federal
Food, Drug, and Cosmetic Act.
